AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15605000
Drug: 35 to
RxNorm normalized name: Hydro 35 Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 to 45 mL injection of 1:10,000 solution of epinephrine for gastric body ulcers
Trial: 15605000
Drug: 15 to
RxNorm normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 to 25 mL injection of 1:10,000 solution of epinephrine for gastric body ulcers
Trial: 9138173
Drug: Cremophor EL-solubilized
RxNorm normalized name: hydroxypropyl cellulose (type EL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor EL-solubilized preparation of vitamin K1 (Konakion drops)
Trial: 9138173
Drug: Mixed-micellar preparation
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-micellar preparation of vitamin K1 (Konakion MM)
Trial: 2083195
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg plus amiloride 5 mg (HA)
Trial: 2083195
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg twice daily (F)
Trial: 2083195
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 10 mg daily (FER)
Trial: 22190065
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg b.i.d. for 5 days)
Trial: 20081560
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for spinal stenosis
Trial: 20081560
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for spinal stenosis with degenerative spondylolisthesis
Trial: 11994341
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g strontium ranelate per day
Trial: 11994341
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g strontium ranelate per day
Trial: 11994341
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g strontium ranelate per day
Trial: 10366258
Drug: Reinforcing Kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcing Kidney and Invigorating Spleen Principle (RKISP) with steroid aerosol
Trial: 10366258
Drug: Steroid aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid aerosol
Trial: 15278814
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch applied for 15 min (Group A)
Trial: 15278814
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch applied for 30 min (Group B)
Trial: 2958035
Drug: P-contrast (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-contrast (1 g/cm3)
Trial: 2958035
Drug: Barium (Mixobar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium (Mixobar Ventrikel 400 mg/ml)
Trial: 31022311
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of mitomycin-C (MMC)
Trial: 31022311
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of saline (placebo)
Trial: 23029716
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg orally, three times a day for 4 weeks
Trial: 20460237
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (6+/‐2 mg/kg)
Trial: 20460237
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (15+/‐2 mg/kg)
Trial: 20460237
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (24+/‐2 mg/kg)
Trial: 20460237
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (34+/‐2 mg/kg)
Trial: 10419812
Drug: Localization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Localization of the AT(1) receptor using immunocytochemistry; expression of prorenin, angiotensinogen, and AT(1) receptor mRNA using RT-PCR.
Trial: 7556823
Drug: Intermittent injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent injections (CIT)
Trial: 1763599
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg alfentanil
Trial: 7073148
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin prophylaxis (5000 U twice daily)
Trial: 31781682
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus (0.5 mg on alternate days for 24 weeks) combined with conventional glucocorticoids and immunosuppressants
Trial: 31781682
Drug: Conventional glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucocorticoids and immunosuppressants
Trial: 17113170
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg once daily for 3-6 weeks, followed by 16 mg once daily for 6 months
Trial: 15066944
Drug: Phenylpropanolamine, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine, 12.5 to 25 mg PO with 16 oz of water
Trial: 15066944
Drug: Phenylpropanolamine, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine, 12.5 to 25 mg PO
Trial: 15066944
Drug: Pseudoephedrine, 30
RxNorm normalized name: Dextromethorphan/Guaifenesin/Pseudoephedrine, 30 mg-600 mg-60 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine, 30 mg PO with 16 oz of water
Trial: 10921031
Drug: ATRA (10(-6)
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA (10(-6) mmol/L)
Trial: 8080349
Drug: Buspirone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone therapy
Trial: 2685709
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (Healon) injection (0.50 to 0.75 ml)
Trial: 2685709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sodium hyaluronate injection)
Trial: 1272686
Drug: Sedative medications
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative medications
Trial: 21851368
Drug: L‐MTAD group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐MTAD group treated with laser irradiation plus a mixture of doxycycline, tetracycline isomer and citric acid
Trial: 21851368
Drug: RC‐Prep group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC‐Prep group treated with EDTA gel or cream (RC‐Prep)
Trial: 16254422
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus nitroglycerin and verapamil (Group A)
Trial: 16254422
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus nitroglycerin (Group B)
Trial: 10639039
Drug: SonoVue 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 0.03 mL/kg
Trial: 10639039
Drug: SonoVue 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue 0.3 mL/kg
Trial: 1587965
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg triamcinolone acetonide aerosol
Trial: 1587965
Drug: 800 mcg
RxNorm normalized name: Biotin 800 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mcg triamcinolone acetonide aerosol
Trial: 1587965
Drug: 1600 mcg
RxNorm normalized name: ACTIQ 1600 MCG Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mcg triamcinolone acetonide aerosol
Trial: 4004963
Drug: Five health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five health status instruments administered before and after total joint arthroplasty
Trial: 30773222
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m2 weekly for up to six doses with 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy
Trial: 29382797
Drug: GSK1995057 (nebulised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1995057 (nebulised TNFR1 antagonist)
Trial: 25837513
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccine
Trial: 19415181
Drug: Temsirolimus 75
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 75 mg, administered orally once daily for 5 days every 2 weeks
Trial: 15161787
Drug: rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (8 mg/day)
Trial: 10327731
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg, twice a day for 3 months
Trial: 1760067
Drug: Dual agent
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual agent therapy (ampicillin and gentamicin)
Trial: 1760067
Drug: Triple agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple agent therapy (ampicillin, gentamicin, and clindamycin)
Trial: 30782938
Drug: Safety Planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Safety Planning Intervention (SPI) with telephone follow-up and treatment as usual, n=80
Trial: 30782938
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual, n=40
Trial: 16707886
Drug: Intramuscular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group)
Trial: 16707886
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy (PT) using oral prednisone 80 mg for 3 consecutive days once every 3 months (PT group)
Trial: 16707886
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group)
Trial: 8431363
Drug: Qualitator daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitator daily diary card for Quality of Life measurement
Trial: 3312789
Drug: Sequential course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential course of 14 days conventional immunosuppression (Lymphocytoglobulin (ALG), azathioprine, steroids) and cyclosporin and steroids thereafter (group A)
Trial: 3312789
Drug: Conventional immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppression for 7 days followed by cyclosporin and steroids (group B)
Trial: 3312789
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with serum creatinine of less than 2 mg/dl at the time of conversion to cyclosporin
Trial: 3312789
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with serum creatinine of more than 2 mg/dl at the time of conversion to cyclosporin
Trial: 31425480
Drug: Vemurafenib (monotherapy)
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib (monotherapy)
Trial: 31394768
Drug: Hot water
RxNorm normalized name: hot water bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot water extract of Curcuma longa L. (WEC) 900 mg tablets containing 400 μg bisacurone, 80 μg turmeronol A, and 20 μg turmeronol B
Trial: 31394768
Drug: Hot water
RxNorm normalized name: hot water bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot water extract of Curcuma longa L. (WEC)
Trial: 26799907
Drug: NO-FEAR Airlines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO-FEAR Airlines (Computer-aided Self-help Treatment); includes psychoeducation, exposure through 6 scenarios with images and sounds related to flying; self-applied via Internet.
Trial: 21178832
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list (no treatment)
Trial: 18513463
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg, 3 times daily
Trial: 18513463
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg, 3 times daily + Ezetimibe 10 mg/day
Trial: 11434162
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (grade II)
Trial: 11434162
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (grade III)
Trial: 11434162
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (grade I)
Trial: 9720838
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg twice daily zinc therapy for 3 months
Trial: 31879782
Drug: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg
Trial: 28576285
Drug: High-dose ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ketamine (1.0 mg/kg)
Trial: 22047811
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of dexamethasone (2 mg)
Trial: 22047811
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of dexamethasone (2 mg)
Trial: 22047811
Drug: Liquid vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid vs Tablet
Trial: 19957671
Drug: Micro-drill treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-drill treatment
Trial: 19957671
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment in PSCO group
Trial: 19957671
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment in NLDO group
Trial: 19957671
Drug: Micro-drill treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-drill treatment in PSCO group
Trial: 19957671
Drug: Micro-drill treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-drill treatment in NLDO group
Trial: 19957671
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment complications
Trial: 19957671
Drug: Micro-drill treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-drill treatment complications
Trial: 16799342
Drug: Supine extubation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine extubation with intravenous lidocaine (group SL)
Trial: 8100611
Drug: Zidovudine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (500 mg twice daily)
Trial: 29479645
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily sitting time
Trial: 18087209
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (rTMS)
Trial: 14667881
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist administered from stimulation day 6
Trial: 14667881
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (serum P <1.2 ng/mL)
Trial: 10978402
Drug: Target Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target Hb of 14 g/dl
Trial: 10978402
Drug: Target Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target Hb of 10 g/dl
Trial: 8642853
Drug: CI-973 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-973 at MTD of 1000 mg/m2 per course
Trial: 8642853
Drug: CI-973 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-973 at doses > or = 1000 mg/m2
Trial: 8642853
Drug: CI-973 therapy
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-973 therapy
Trial: 1848289
Drug: Sintered hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintered hydroxyapatite implant material
Trial: 6229864
Drug: Ipratropium nasal
RxNorm normalized name: ipratropium nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium nasal spray
Trial: 1441734
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (3 intramuscular injections at months 0, 1, and 2)
Trial: 2863799
Drug: ACC‐9447 (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC‐9447 (topical beta adrenergic antagonist)
Trial: 24032192
Drug: Common acupuncture
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common acupuncture therapy
Trial: 18543482
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with intravenous injection of 20 mg Omeprazole once a day for 3 successive days.
Trial: 16415703
Drug: Sertraline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25 mg/d for 1 week, then 50 mg/d for 15 weeks)
Trial: 10818030
Drug: Anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation treatment (warfarin) after individualised decision analysis
Trial: 10818030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription
Trial: 8867905
Drug: GL-METF (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GL-METF (2.5 mg glibenclamide and 400 mg metformin)
Trial: 8867905
Drug: GL-PHEN (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GL-PHEN (2.5 mg glibenclamide and 25 mg phenformin)
Trial: 29366513
Drug: Vibegron 50mg
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron 50mg once daily
Trial: 29366513
Drug: Vibegron 100mg
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vibegron 100mg once daily
Trial: 29366513
Drug: Imidafenacin 0.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1mg twice daily
Trial: 22700039
Drug: Galantamine (GAL)
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine (GAL) 8 mg/day
Trial: 21029662
Drug: rhTNFR:Fc 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNFR:Fc 0.4 mg/kg, subcutaneously injected twice weekly
Trial: 21029662
Drug: MTX 10
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 10 mg × m(‐2) × w(‐1)
Trial: 21029662
Drug: SASP 30‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SASP 30‐50 mg × kg(‐1) × d(‐1) (for intolerance patients)
Trial: 8934215
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose administration (75 g)
Trial: 8934215
Drug: Pyridostigmine (PST,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PST, 120 mg)
Trial: 31542391
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg and Quercetin 1000 mg for 3 days
Trial: 29595449
Drug: Continuous oxygen
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oxygen (3 l/min if baseline oxygen saturation ≤ 93%, 2 l/min if > 93%) for 72 hours after randomisation
Trial: 25199313
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg x kg(‐1))
Trial: 25199313
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg x kg(‐1)) plus Cooling
Trial: 22302296
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg NTG skin spray